Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03107390

Acronym

NT-pro-MICI

Enrollment

159

Registered

2017-04-11

Start date

2013-10-28

Completion date

2017-08-07

Last updated

2020-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases, NT-pro-BNP

Brief summary

NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology. Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.

Interventions

OTHEREvaluate the blood level of NTproBNP

Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult subjects (age 18 years) * MICI Group: Patients monitored for probable HC or MC * Control group: Patients referred for consultation in gastroenterology with a clinical and endoscopic picture eading to the diagnosis of TF I * Person who agreed to participate in the study * Patient covered by social insurance

Exclusion criteria

* Causes of increased concentrations of natriuretic peptides: acute heart failure, acute or chronic pulmonary disease with right ventricular repercussion, valvulopathies, primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes, cirrhosis with ascites, cancers, chronic renal insufficiency. * Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory syndrome * Ongoing treatment that may affect the concentration of natriuretic peptides: ACE inhibitor, angiotensin II receptor antagonists, diuretics * Patient deprived of liberty or protected major (under guardianship or curatorship)

Design outcomes

Primary

Measure	Time frame
Blood level of NTproBNP.	1 month

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026